LIVE · PREMARKET
VOL. VII · ISSUE 114TUE · JUN 9 · 2026Sign in
Daily Fact

💊Epidiolex, the first FDA-approved cannabis-derived drug, treats severe childhood epilepsy and generated $800M+ in annual revenue.Jazz Pharmaceuticals

Cover Story — Market Intelligence, Unfiltered

The Commonwealth in Limbo: How Virginia Built a Cannabis Market for Everyone Except Cannabis Companies

Five years after becoming the first Southern state to legalize, Virginia still has no legal way to buy weed. On May 19, 2026, Gov. Abigail Spanberger — who campaigned on signing exactly this bill — became the third Virginia governor in a row to veto retail cannabis, this time against her own party's trifecta. The story runs through Total Wine's hemp-THC lobby, an FBI raid on Sen. Louise Lucas's dispensary, $700M in forgone tax revenue bleeding to Maryland, and a regulator built to regulate nothing. The earliest plausible adult-use retail launch in Virginia is now 2028.

Daily
Published each morning
6:00 AM ET
Delivered to your inbox
Independent
No ads. No strings.
No sales
Just information
The Latest
View all →
Culture

The Quiet Substitution: Why the People Who Actually Switched From Beer to THC Are Switching All the Way

7 min read
Culture

Louis Armstrong's 40-year romance with cannabis

7 min read
Culture

After RFK: The Cannabis Festival Trail Still Has Three Big Stops Left

8 min read
Federal Policy

The MSO Uplisting Question: Why Nobody Agrees, and What's Actually True

15 min read
From the Desks
The Culture Desk

From Congo Square to Cinema Village: The Quiet Triumph of Cannabis! A Viper Vaudeville

Baba Israel and Grace Galu have spent four years turning Martin A. Lee's Smoke Signals into a touring music-theater piece that puts Black cultural authorship at the center of the cannabis story. In April it played a sold-out preview at Nublu; in May the accompanying documentary opened at Cinema Village. The most interesting cultural artifact of the legalization era isn't on a dispensary shelf — it's on stage.

The Federal Policy Desk

Green Thumb Is Paying $70 Million a Year to License Its Own Brands

Green Thumb's Q1 looks clean by cannabis standards: $300M revenue up 7.4% YoY, $76M operating cash flow, $54.6M net cash, an aggressive buyback. But starting Q2, GTI begins paying $70 million a year in fixed brand-licensing fees to RYTHM, Inc. — a separately Nasdaq-listed holding company chaired by GTI's own CEO. The $15.4M net income was flattered by a $17M Ascend arbitration win and $6.5M RYTHM equity income; strip those out and operating income actually declined year-over-year. The DEA registration filing, the Texas TCUP license, and the dual-entity architecture all telegraph one thing: Green Thumb is engineering itself into something that isn't quite a cannabis operator anymore.

The Federal Policy Desk

The White House's Cannabis Contradiction: Rescheduling with One Hand, Criminalizing with the Other

On May 4, ONDCP released the 2026 National Drug Control Strategy — and lumped state-legal marijuana alongside fentanyl and gas station heroin, eleven days after DOJ moved medical cannabis to Schedule III. The contradiction is statutory, but it lands hard on hemp-derived THC operators staring down a November deadline and adult-use companies awaiting the June 29 DEA hearing.

The Federal Policy Desk

The $99 Million Line Item Curaleaf Doesn't Want You to Overthink

Curaleaf's $70M Q1 profit was a 280E reversal in disguise — strip out the $98.7M one-time tax benefit and pre-tax operating losses actually widened 74% year-over-year. The headline beat masks compressing margins, a 1.3% FCF margin, and an 11.5% bond coupon. The real story is structural: a BDO auditor swap, DEA registration filings, the completed Four 20 Pharma consolidation, and a quiet domestic wholesale pivot. Curaleaf is methodically rebuilding its infrastructure for a major-exchange uplisting.

Schedule Watch

The road to Schedule III

Tracking every step of the federal rescheduling process — from Biden's 2022 review order through Trump's executive action and the April 23 DOJ order moving medical cannabis to Schedule III, to the June 29 Phase Two hearing on full rescheduling.

Oct 2022
Biden orders scheduling review
Aug 2023
HHS recommends Schedule III
May 2024
DEA proposes rescheduling rule
Aug 2024
42,000+ public comments received
Dec 2025
Trump signs executive order
Jan–Apr 2026
Biden-era ALJ proceeding withdrawn
Apr 23, 2026
DOJ orders medical cannabis to Schedule III
Jun 29 – Jul 15, 2026
Phase Two hearing on full reschedulingIn progress
Late 2026
Final rule on full rescheduling
The Daily Brief

Six a.m. Eastern. Before the market opens.

One email. The night's moves, the morning's agenda, and three things every operator needs to know before 9:30.

Free · No spam · Unsubscribe anytime